510 related articles for article (PubMed ID: 33749159)
1. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
Yan Y; Liu B; Du J; Wang J; Jing X; Liu Y; Deng S; Du J; She Q
ESC Heart Fail; 2021 Jun; 8(3):2210-2219. PubMed ID: 33749159
[TBL] [Abstract][Full Text] [Related]
2. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.
Zafeiropoulos S; Farmakis IT; Milioglou I; Doundoulakis I; Gorodeski EZ; Konstantinides SV; Cooper L; Zanos S; Stavrakis S; Giamouzis G; Butler J; Giannakoulas G
JACC Heart Fail; 2024 Apr; 12(4):616-627. PubMed ID: 37656079
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA
JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860
[TBL] [Abstract][Full Text] [Related]
5. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
[TBL] [Abstract][Full Text] [Related]
6. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
[TBL] [Abstract][Full Text] [Related]
7. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.
Kim HM; Hwang IC; Choi W; Yoon YE; Cho GY
Sci Rep; 2021 Nov; 11(1):22342. PubMed ID: 34785723
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction: a meta-analysis.
Huang Y; Fang C; Zhang Y; Ma L; Zhou H; Ye H
J Cardiovasc Med (Hagerstown); 2023 Feb; 24(2):123-131. PubMed ID: 36583980
[TBL] [Abstract][Full Text] [Related]
9. ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial).
Jariwala P; Jadhav K; Punjani A; Boorugu H; Mari AR
Indian Heart J; 2021; 73(5):605-611. PubMed ID: 34627577
[TBL] [Abstract][Full Text] [Related]
10. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
[TBL] [Abstract][Full Text] [Related]
11. Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction.
De Marzo V; Savarese G; Tricarico L; Hassan S; Iacoviello M; Porto I; Ameri P
J Intern Med; 2022 Aug; 292(2):333-349. PubMed ID: 35332595
[TBL] [Abstract][Full Text] [Related]
12. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
Zhao M; Xin Y; Li J; Cao X; Liu X
Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Sreenivasan J; Malik A; Khan MS; Lloji A; Hooda U; Aronow WS; Lanier GM; Pan S; Greene SJ; Murad MH; Michos ED; Cooper HA; Gass A; Gupta R; Desai NR; Mentz RJ; Frishman WH; Panza JA
Cardiol Rev; 2024 Mar-Apr 01; 32(2):114-123. PubMed ID: 36576372
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
Yan BW; Spahillari A; Pandya A
Circ Cardiovasc Qual Outcomes; 2023 Jun; 16(6):e009793. PubMed ID: 37278232
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis.
Mo X; Lu P; Yang X
Clin Cardiol; 2023 Oct; 46(10):1137-1145. PubMed ID: 37465885
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of three novel drugs in the treatment of heart failure: A network meta-analysis.
Luo L; Yang X; Tang K; Wu J; Li D; Ran J; Zhang L; Wang D; Zhao D; Yu M; Chen A; Saranathan M
Medicine (Baltimore); 2022 Jul; 101(29):e29415. PubMed ID: 35866831
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
[TBL] [Abstract][Full Text] [Related]
20. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
